United States Polycythemia Market 2025 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market size and Growth

The Global Polycythemia Market reached US$ 5.89 billion in 2024 and is expected to reach US$ 12.41 billion by 2033, growing at a CAGR of 6.7% during the forecast period 2025-2033.

Key Development:

United States: Recent Industry Developments

✅ October 2025 - Johnson & Johnson is in advanced talks to acquire Protagonist Therapeutics, aiming to bolster its immunology and hematology portfolios. The acquisition would provide J&J access to rusfertide, a promising PV treatment developed in collaboration with Takeda

✅ August 2025 - The FDA granted Breakthrough Therapy Designation to rusfertide for PV, accelerating its development and review process.

✅ June 2025 - Protagonist Therapeutics and Takeda presented Phase 3 VERIFY study results, demonstrating rusfertide's efficacy in reducing phlebotomy needs and improving hematocrit control in PV patients.

✅ March 2025 - Ono Pharmaceutical entered into a global license agreement with Ionis Pharmaceuticals for sapablursen, an investigational RNA-targeted medicine for PV treatment. Ionis received $280 million upfront and up to $660 million in development, regulatory, and sales milestones.

✅ January 2025 - Agios Pharmaceuticals announced plans to file a New Drug Application for AG-236, an siRNA targeting TMPRSS6, for PV treatment by mid-2025.

Japan: Recent Industry Developments

✅ June 2025 - PharmaEssentia announced the expected U.S. launch of the Ropeg pen injector in 2025, aiming to enhance treatment accessibility and ease for PV patients.

✅ June 2025 - Silence Therapeutics presented updated Phase 1 data for Divesiran at EHA 2025, highlighting its potential as a first-in-class siRNA treatment for PV.

✅ March 2025 - Ono Pharmaceutical entered into a global license agreement with Ionis Pharmaceuticals for sapablursen, an investigational RNA-targeted medicine for PV treatment.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/polycythemia-market?sb

Polycythemia is a condition characterized by an abnormal increase in red blood cell count, which can thicken the blood and impair circulation. It may be primary (due to bone marrow disorders) or secondary (caused by chronic low oxygen levels), and management includes phlebotomy, medications, and treatment of underlying causes.

Key Players:

=> Novartis AG, Incyte Corporation, Bristol-Myers Squibb Company, PharmaEssentia Corporation, TAJ LIFE SCIENCES PVT. LTD, Genetec Lifesciences, Teva Pharmaceuticals, Medyra Pharmaceuticals, Viatris, Apotex Inc and among others.

Growth Forecast Projected:

The Global Polycythemia Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2033. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Polycythemia Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=polycythemia-market

Key Segments:

➥ By Type: Primary polycythemia, Secondary polycythemia, Pseudopolycythemia

➥ By Drug Class: Antimetabolites, Hydroxyurea, Methotrexate, Cytarabine, JAK2 inhibitors, Myelosuppressive Agents, Selective Serotonin Reuptake Inhibitors, Folic acid, Others

➥ By Route of Administration: Oral, Intravenous, Intramuscular

➥ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Analysis for Polycythemia Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Polycythemia producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Polycythemia revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/polycythemia-market?sb

FAQ

What is the current size of the Polycythemia Market?

A: In 2024, the Polycythemia Market was valued at US$ 5.89 billion, reflecting its strong industry presence.

Q2: How large is the Polycythemia Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Polycythemia Market will grow to around US$ 12.41 billion , demonstrating significant expansion.

Q3: What is the growth rate of the Polycythemia Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 6.7% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.